|
Stem Cell Factor Medication for Aplastic Anemia Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Stem Cell Factor Medication for Aplastic Anemia conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Stem Cell Factor Medication for Aplastic Anemia Clinical research trials and Stem Cell Factor Medication for Aplastic Anemia medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Stem Cell Factor Medication for Aplastic Anemia. Stem Cell Factor Medication for Aplastic Anemia Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Stem Cell Factor Medication for Aplastic Anemia clinical trial. Participants oftentimes recieve the finest healthcare available for their Stem Cell Factor Medication for Aplastic Anemia condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Stem Cell Factor Medication for Aplastic Anemia  Stem Cell Factor Medication for Aplastic Anemia
Stem Cell Factor Medication for Aplastic Anemia
For Condition: Aplastic Anemia,Pancytopenia
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: This trial, sponsored by Amgen, Inc., which produces the recombinant methionyl human stem cell factor (r-metHuSCF), also involves two other institutions. The primary objective is determination of the safety of administering multiple doses of r-metHuSCF in the setting of acquired aplastic anemia and evaluation of the effect of r-metHuSCF on peripheral blood counts. Potential effects of r-metHuSCF on frequency of need for red cell or platelet transfusions and on bone marrow morphology/cellularity will also be evaluated.
Details: This trial, sponsored by Amgen, Inc., which produces the recombinant methionyl human stem cell factor (r-metHuSCF), also involves two other institutions. The primary objective is determination of the safety of administering multiple doses of r-metHuSCF in the setting of acquired aplastic anemia and evaluation of the effect of r-metHuSCF on peripheral blood counts. Potential effects of r-metHuSCF on frequency of need for red cell or platelet transfusions and on bone marrow morphology/cellularity will also be evaluated.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Acquired moderate or severe aplastic anemia. Intolerant to, or failure to durably respond to, ATG/ALG therapy with or without cyclosporin. Patients may not have received ATG/ALG, therapy for 12 weeks prior to enrollment or cyclosporin for 4 weeks prior to enrollment. Two years of age or older. Karnofsky Performance Status greater than or equal to 60 percent. Adequate organ function as defined by serum creatine less than 2.0 mg/dl and a bilirubin less than 2.0 mg/dl. Patients (or their parent[s]/responsible guardian[s]) must be able to comprehend and be willing to sign an informed consent prior to starting r-metHuSCF therapy. No current diagnosis or past history of myelodysplastic syndromes. No diagnosis of Fanconi's anemia, dyskeratosis congenita, or other congenital forms of aplastic anemia. No current diagnosis of clinically active paroxysmal nocturnal hemoglobinuria (PNH) defined as patients with clinically significant thrombosis or hemolysis. No diagnosis of eosinophilic fasciitis. No treatment with ATG, ALG, or other immunosuppresive agents within 12 weeks of enrollment or treatment with cyclosporine A or IL-3 within 4 weeks of enrollment. No treatment with hematopoietic growth factors within 2 weeks of enrollment. No evidence of active uncontrolled infection. No known allergy to Ecoli-derived products. No current or recent symptoms of asthma occurring within the past 10 years (including allergic asthma, or asthma induced by cold temperature, infection, or exercise). No history of anaphylactic/anaphylactoid-type event manifested by disseminated urticaria, laryngeal edema, and/or bronchospasm (or for example: food, insect bites, etc). Patients with drug allergies, manifested solely by rash and/or urticaria, are not excluded. An isolated episode of urticaria occuring more than 3 years earlier is not a contraindication. No significant nonmalignant disease including previously documented HIV infection, uncontrolled hypertension (diastolic blood pressure greater than 115 mmHg), unstable angina, congestive heart failure (greater than NY Class II), poorly controlled diabetes, coronary angioplasty within 6 months, or uncontrolled atrial or ventricular cardiac arrhythmias. No pregnancy or breast feeding. Those of childbearing potential must observe adequate birth control measures. No treatment with an investigational agent (other than hematopoietic growth factors) within 4 weeks of study entry. No concurrent use of beta adrenergic blocking agents. No concurrent use, or use within the past 2 weeks, of Monoamine Oxidase Inhibitors (MAO Inhibitors). No psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participation in this study.
Total Enrollment: 40
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 940016; 94-H-0016
Study Start Date: October 21, 1993
Record last reviewed: June 19, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001398
Other Aplastic Anemia Studies:
1. Stem Cell Factor Medication for Aplastic Anemia
2. Gene Therapy for the Treatment of Fanconi's Anemia Type C
3. Screening for Hematology Branch Protocols
4. Evaluation, Treatment, and Training for Patients with Blood Disorders
5. Collection of Blood from Patients with Pancytopenia
Related Studies:
Other Aplastic Anemia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Stem Cell Factor Medication for Aplastic Anemia
|
|
|
|
|
|
|
|
